Skip to content
thestock.space

On 6 Nov 2026, Concord Biotech was priced at ₹632.60, or 47.4× trailing earnings, against an industry P/E of 49.1×, and the shares are 22% below their 52-week high. It earns ROCE of 17% and ROE of 14%, and sales and net profit grew 8.0% and 2.8% a year over 3 years. It has almost no debt, and its dividend yield is 0.6%. It is a small-cap company with a market cap of ₹13,236 Cr, ranked 4th of 20 Biotechnology companies by market cap; the shares fell 7.5% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹656.00
Day high
₹663.00
Day low
₹622.30
Prev. close
₹672.70
Volume
2.6 L

Health check

2 good · 3 fair · 1 to check
  • ReturnsIn line

    −7.5% over a year, better than 3 of 7 peers.

  • Price tagIn line

    P/E 47.4 vs industry 49.1.

  • GrowthSlow

    Sales +8.0%, profit +2.8% a year over 3 years.

  • ProfitabilityAverage

    ROCE 16.7% vs peer median 2.8%.

  • Balance sheetSolid

    Practically debt-free, Piotroski 7 of 9.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Biotechnology

19 listed peers. Screen the industry

Small cap

₹13,236 Cr, #4 of 20 in its industry by size.

Defensive

Beta 0.44 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Sep 2026: sales ₹1,170 Cr · profit ₹282 Cr
Market cap
₹13,236 Cr
Small cap
P/E
47.4
Industry 49.1
Price to book
6.48
Peers 4.52
Dividend yield
0.60%
ROE
14.3%
Peers 1.6%
ROCE
16.7%
Peers 2.8%
Debt to equity
0.00
Debt ₹1.75 Cr
EPS (TTM)
₹13.35
Face value ₹1
OPM (TTM)
34.5%
Net margin 24.1%
Sales growth
+25.1%
Latest quarter vs a year ago
Profit growth
+11.1%
Latest quarter vs a year ago
Price to sales
11.31
EV/EBITDA 31.4

Strengths and risks

Strengths

  • Practically debt-free.
  • Quarterly sales up 25.1% on a year ago.
  • Net margin of 24.1%.
  • Positive operating cash flow in each of the last 4 years.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Concord Biotech

Concord Biotech Limited, a, biopharma company, engages in the research and development, manufacture, and sale of pharmaceutical products in India and internationally. It operates through Active Pharmaceutical Ingredients (APIs) and Formulations segments. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate…

Headquarters
Ahmedabad
Employees
1,624
Sector
Healthcare
ISIN
INE338H01029
Website
concordbiotech.com

Price range

52 weeks

₹493.50₹807.50

Today

₹622.30₹663.00
Avg volume (3M)
3.3 L
1-year return
minus 7.5%
From 52-week high
minus 21.7%

Analyst consensus

5 analysts
BuyMean target ₹760.00 plus 20.1%

Target range, with today’s price

Low ₹680.00High ₹850.00

Today’s price ₹632.60 is below the lowest analyst target.

Consensus from Yahoo Finance. Not a recommendation.

Peers · Biotechnology

Compare with peersScreen the whole industry
Company
BIOCONBiocon365.10plus 0.86%59,794122.51.732.8%1.0%19.4%15.3%−5.9%0.14%minus 4.9%
ANTHEMAnthem Biosciences915.55plus 0.22%51,59484.615.7426.8%20.4%41.4%26.2%15.4%0.22%plus 30.1%
ONESOURCEOnesource Specialty Pharma1,599.80plus 1.13%18,346–3.100.3%0.0%23.5%232.3%–0.00%minus 13.7%
CONCORDBIOConcord Biotech632.60minus 5.96%13,23647.46.4816.7%14.3%34.5%8.0%2.8%0.60%minus 7.5%
BLUEJETBlue Jet Healthcare553.80minus 3.91%9,60734.54.5224.0%19.9%31.4%9.4%15.7%0.22%minus 5.0%
SUPRIYASupriya Lifescience695.80minus 19.99%5,60028.24.6822.3%19.1%21.4%21.2%32.5%0.14%plus 9.2%
ZOTAZota Health Care1,231.10plus 1.01%4,264–6.82−7.3%−24.1%0.1%56.7%–0.08%minus 21.9%
DCALDishman Carbogen Amcis156.64minus 0.56%2,456152.10.372.7%1.6%16.1%7.5%–0.00%minus 47.1%
Median of 7 peers–0.22%9,60784.64.522.8%1.6%21.4%21.2%15.5%0.14%−5.0%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrSep 25Dec 25Mar 26Jun 26Sep 26
247278326257309
159179208175205
88.59911982.4104
35.8%35.6%36.4%32.0%33.8%
15.69.315.214.19.5
0.10.10.100
18.418.719.518.118.4
–−3.3–––
85.786.211478.395.5
26.4%26.1%22.4%26.4%27.1%
63.663.688.857.770.7
6.036.088.468.466.65

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+8.0%
Profit CAGR 3Y
+2.8%
EPS CAGR 3Y
+2.6%
ROE
14.3%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
8319981,1801,046
–+20.2%+18.2%minus 11.3%
472558662667
359440518379
43.2%44.1%43.9%36.2%
17.514.69.722.2
4.52.60.50.3
5453.654.474.5
4.214.22217.9
322413495345
25.4%25.3%24.9%24.8%
240308372261
–+28.3%+20.6%minus 29.8%
22.9529.4535.5224.78

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
10.510.510.510.5
1,2801,5161,8022,007
31.59.732.3
192164219215
1,5141,7012,0342,235
773794852876
18021957.687.8
0.1–2284.9
181286335407
379401768780
1,5141,7012,0342,235

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
246265245267
−158−155−160−143
−85.2−99.2−98.8−113
2.811.6−14.211.3
−145−85.7−111−95.2
101180133172
−53.6−71.5−91.5−112

Shareholding pattern

Source: NSE filings
44.1%
promoters
  • Promoters44.09%
  • Public55.91%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202644.09%55.91%plus 0.01
30 Jun 202644.08%55.92%0.00
31 Mar 202644.08%55.92%0.00
31 Dec 202544.08%55.92%0.00
30 Sep 202544.08%55.92%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you